I have been managing my retirement fund for the last several years. And when it grows sufficiently... I will retire. I started investing when I rolled over a 401k from a previous employer into an IRA that I managed myself. That was a few months before the meltdown of 2008-2009 - a true trial by fire. During that time I discovered that I do not panic easily. Good to know! I experience large losses on paper, but in the crisis I saw opportunity. I nabbed CBS, GE, and a few other great American companies at insanely low prices in March 2009. Those stocks saved my bacon over the next couple years. These days, I tend to favor technology and biotech stocks that look promising but are currently under-appreciated. I have always been a computer geek, and I used to teach high school biology, and have been overall a fan of science. There is a real technological revolution going on, particularly in healthcare, and I'm glad to be alive to witness it. And to invest in it. I look for great value, then buy and hold. I occasionally pick a dog, but the good ones have been quite good. I only trade when better opportunities for value and growth present themselves. Glad to say that I'm at least closer to retirement than I would have been if I left it all in a 401k to be managed by some hedge fund asswipe. Still a long way to go, though. :)
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
Kiran is an independent research consultant in the areas of volatility-based and leveraged instruments, including several proprietary strategies.
His services include hypotheses generation, back-testing, risk/return analytics, and predictive modelling for proprietary trading strategies, as well as research consulting in the above areas. Expected and realized returns for his 2 flagship strategy portfolios exceed 100% on an annualized basis, while maintaining expected and realized Sharpe ratios over 3 times higher than the S&P 500. Kiran was mentored by Wall Street research veteran Mark Gomes. Alongside Mr. Gomes, he brought Wall Street level research to retail and institutional investors through PTT Capital's flagship newsletters.
EXP is a graduate from The University of Wall Street and serves with the goal to assist the small to mid-level investor maneuver through the treacherous waters controlled by Hedge Funds and Market Makers. SA followers only see a very small part of EXP's published research. This is not an easy business. Wall Street trickery is at an "All Time High" these days; brutally fierce and rampant against small retail investors. Trading is psychological in nature, meaning that the market's psychological warfare can be extremely debilitating. EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities and then manage to act on them. EXP resides in the USA, and is thankful to followers worldwide. You can also follow EXPstocktrader on: Twitter --- @EXPstocktrader Email --- firstname.lastname@example.org Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some compensation is paid by SA if the article gets picked for circulation, that's it. Prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader and Seeking Alpha are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
I have been investing in biotech companies for multiple years, with special focus towards the small-cap sector and catalyst plays. There is lots of money to be made in the volatile period around catalyst dates of trial results and FDA decisions.
Currently pursuing a Computing Engineering degree, but I also enjoy the constant learning that comes with investing in biotech companies.
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
Individual investors should feel free to message me privately about my real-time subscription service, which is very affordable. That is also included with my short idea product for institutional investors, here on Seeking Alpha.
For a better mobile experience on Seeking Alpha click the top right menu icon on most browsers and select "request desktop site".
I am a former financial communications programmer, turned full-time investor. I began investing in the mid-1990s, looking for a way to achieve early retirement. (A goal in which I have succeeded, if you don't consider full-time investing a job.) I took a scientific, experiment-based approach rather than a studious one. I feel that this approach, combined with my extensive programming work in financial markets and directly with traders has given me uncommon contrarian insight into what really drives market dynamics.
To that end, my articles will center around stocks and their derivatives because that's where I have the most experience (over 20 years). I may occasionally comment on currencies, where I believe I have a sound academic knowledge, but less trading experience.I will always refer to a company by name or some abbreviation thereof. By contrast, I will refer to the stock a company issues by its ticker symbol. I think it can be important to differentiate between the two.
I specialize in Biotech companies. After following the sector for many years, it's my belief that a logical analysis of publicly disclosed information on a Biotech company often includes sufficient data to draw the parallels necessary to invest intelligently.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Joseph has been an analyst, investor, and student of economic theory; money and banking; and statistical methods for evaluating and implementing risk/reward trading algorithms since 1972. Joseph is also an occasional contributor to financial publications and his essays are frequently cited by other financial websites and publications.
Since the end of the Great Recession, Joseph came to recognize that traditional methodologies for forecasting economic growth and investment asset pricing are no longer of value, and a broader understanding of the post Glass Steagall, financially engineered world that has driven markets and economies since the turn of the century is required today.
He has a good grasp of Shadow Banking, High Frequency Trading, and Dark Pools, and their impact on today’s markets. He has also spent considerable time understanding the new global paradigm of central bank involvement in experimental policy designed to better control economies.
Joseph doesn’t subscribe to a specific school of theory on economics. Rather, his thinking is based on a combination of the Classical School, the Austrian School, and the Keynesian School. He even sees the writings of Karl Marx as particularly instructive.
Joseph is particularly fond of the following quote from Albert Einstein and sees his own work as driven by that same passionate curiosity that Einstein refers to:
“I have no special talents. I am only passionately curious.”
Coming in a close second in terms of favorite quotes that express his views, Joseph embraces Lord Acton’s views expressed here:
“The danger is not that a particular class is unfit to govern.
Every class is unfit to govern."
James Altucher was the managing director of Formula Capital, an asset management firm and fund of hedge funds. He's written five books on investing: Trade Like a Hedge Fund, Trade Like Warren Buffett, SuperCash, The Forever Portfolio, and his latest book, The Choose Yourself Guide To Wealth. He currently writes at Jamesaltucher.com and has released a newsletter, The Altucher Report.
Mr. Altucher is the founder of Stockpickr.com, a social network for finance that had millions of unique visitors per month when it was sold to TheStreet.com in 2007. He has written over 200 columns for The Financial Times and has written for TheStreet.com, Forbes, Yahoo Finance, Fidelity.com, and other publications. He was also the founder of a web services firm, Reset Inc, which he sold in 1998, at which time he became a partner at VC firm, 212 Ventures/Investcorp. Mr. Altucher regularly appears on CNBC, Fox News, Fox Business, and CNN Radio, and is also in his spare time a nationally ranked chess master. Mr. Altucher received his BA at Cornell University and attended graduate school for computer science at Carnegie Mellon University.
You can follow him on twitter @jaltucher.
Former Investment Representative with large private firm with seat on NYSE. BBA degree in Marketing. Now working as a Rail Traffic Controller for one of the nations largest railroads.
Have been investing in stocks for over 25 years. Consider myself an investor, not a trader. Believe day trading is a losers game and that most who partake are wasting their lives and will end up broke. Most holdings held for months, some for years.
Favorite companies to invest in include: 1) Companies that are experiencing increases in institutional ownership and/or reductions in short positions (and especially if "analyst" continue to bash the stock while this is occurring, wink wink), 2) Biotechnology companies that have sold off dramatically after receiving FDA approval as traders lose patience with the speed of the drugs roll-out or ramp up, 3) Companies on the cusp of profitability but whose price does not yet reflect it, 4) Established companies whose shares have been beat down relentlessly but whose price has put in a solid (and preferably tested) base that's now rising at some price not too far removed from their 52-wk lows, 5) Companies that multiple hedge funds have started to take large positions in, and 6) Companies that can raise money cheaply without diluting shareholders into oblivion.
Avoid: 1) Stocks trading under $1.00, 2) Stocks rising in conjunction with spikes in message board chatter, buyout rumors, or because they are being pumped somewhere, and 3) Stocks whose EPS are the inverse of their share price... or even close.
Lawrence is the Managing Director of Fuller Asset Management. He has 20+ years of experience managing investment portfolios and serving the needs of individual clients. He began his career as a Financial Consultant in 1993 with Merrill Lynch. He worked for First Union Brokerage, Morgan Stanley and ING in the same capacity before realizing his long-term goal of complete independence. He graduated from the University of North Carolina at Chapel Hill with a B.A. in Political Science in 1992.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
I am a retired accountant with a background in large mining projects from feasibility to full-scale operation.
I manage my own investments and for the majority of my portfolio I have a strong preference for Blue Chip stocks.
For the balance of my portfolio I have an interest in small and micro-cap stocks, seeking superior returns.I seek alpha returns through identifying companies with the right fundamentals and assessing the risks and investing long. Although investing long, I understand the importance of share price in the short to medium term for these small cap companies as it impacts their ability to raise capital.
Jason Cimpl is a Research Analyst at Wyatt Investment Research who focuses on stock analysis and active trading. His financial career also includes auditing and mutual fund research.
Jason started at Wyatt Investment Research in 2007 and has been the lead researcher for several of their newsletters. His most popular service was TradeMaster, a swing trading service that ran from 2008 to April 2012. Under Jason’s guidance, readers of TradeMaster participated in astounding yearly gains during the newsletter’s lifetime - such as 44.5% in 2010 and 63.2% in 2011.
Today, he invests his personal time studying aggressive swing trading strategy and remains the lead equity analyst of Top Stock Insights - a post he's held since its inception - and a daily contributor to The Daily Profit.
David Hunkar (pseudonym) holds a Masters Degree in Finance and Economics. He is a part-time consultant for a financial consulting firm where he manages portfolios for manages portfolios for self and family. He has been an investor for the past ten years. David focuses on foreign stocks trading in the US markets including the OTC market. He concentrates on high dividend yield and dividend growth stocks. ETFs are his another favorite investment vehicle. In addition to his contributions here at Seeking Alpha, you can also visit him at his blog www.topforeignstocks.com
Jason Schwarz authors the popular Economic Timing investment newsletter. His fundamental and technical research has become a primary resource for hedge funds and individual investors.
Nick Gogerty he has worked at a value based hedge fund, a quant forex desk and debt prop desks, various technology and marketing firms and a deep future science research lab as well as one of the world's largest hedge funds. He is to be a guest lecturer at Columbia's Value Investing program fall 2014 and wrote, The Nature of Value published by Columbia University Press.
His experience and passion runs deeply across multiple market sectors, audiences and geographies.
Mr Gogerty has lived in 6 countries across 3 global regions, solving complex business problems.
Previously, Mr. Gogerty developed commodity hedge fund portfolios and indexes, working as a quantitative developer and trader on a proprietary foreign exchange desk in London. In addition, Mr. Gogerty has been a serial entrepreneur in convergence spaces between technology and media. He has also testified before the U.S. Senate on technology and counter-party financial risk with regard to the year 2000 transition.
Mr. Gogerty holds a Bachelor of Arts in cultural anthropology from the University of Iowa, an M.B.A. from the Ecole de Ponts et Chaussees in Paris. He holds or has held Series 3, 7, 63 and FSA licenses. Nick holds the Chartered Alternative Investment Analyst (CAIA) (http://www.caia.org/) designation. Mr. Gogerty lives in New York City with his wife Mercedes, where he enjoys reading about finance, technology, design, applied science and sustainable development in emerging economies. visit www.thenatureofvalue.com
Brandon Matthews (pseudonym) is the founder of SatwavesPro.com, which was borne of his desire to help retail investors after witnessing the continually changing ways that Wall Street can cheat them. Brandon has worked for Monroe Parker Investment Bankers, Morgan Stanley Dean Witter, American Express Financial Advisors, David Lerner Associates and a private equity firm as a stock and bond broker.
Brandon held Series 7, 63, 65, 31, Life, Health, Variable Annuity and Variable Life Securities and Insurance Licenses and was a registered investment advisor in New York, New Jersey, Florida and Connecticut.
Brandon combines an expertise in point & figure technical analysis with basic fundamental research to provide actionable recommendations.
Brandon is a Gold Level Contributor to Seeking Alpha and a top ranked author, had a significant role as an expert in the documentary Stock Shock, and is working on his first book.
Robert Freedland is a medical professional by trade and an amateur investor who has been blogging on Stock Pick Bob's Advice since 2003. He has been investing in the stock market for 46 years, having made his first purchase at the age of 13 of five shares of Global Marine in September 1967. He enjoys sharing his philosophy and perspective on investing, both by blogging and podcasting. Visit Bob's blog: Stock Pick Bob's Advice (http://bobsadviceforstocks.tripod.com/bobsadviceforstocks/). Since 2009, he has been managing portfolios on Covestor, which now include Growth and Momentum (http://covestor.com/robert-freedland/growth-and-momentum), Sustained Momentum (http://covestor.com/robert-freedland/sustained-momentum), Healthcare (http://covestor.com/robert-freedland/healthcare) and Large Cap Momentum (http://covestor.com/robert-freedland/large-cap-momentum).